Loading clinical trials...
Loading clinical trials...
Assessment of Deep Gray Matter Anatomic Changes in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With Gilenya® (Fingolimod) With and Without Cognitive Impairment Over a 2 Year Period Using 3 Dimensional Volumetric MRI Studies (NeuroQuant, NeuroQuarc) and Automated Neuropsychological Assessment Matrices (ANAM)
Conditions
Interventions
NeuroQuant
Automated Neuropsychological Assessment Matrices
+2 more
Locations
1
United States
The George Washignton University
Washington D.C., District of Columbia, United States
Start Date
December 1, 2013
Primary Completion Date
September 1, 2016
Completion Date
December 1, 2016
Last Updated
January 13, 2023
NCT05359653
NCT06390930
NCT03401879
NCT06389968
NCT05834855
NCT06413602
Lead Sponsor
George Washington University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions